Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6207)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2013 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S, Rahman T. Vildagliptin |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i6/358.htm |
| Number | Citing Articles |
| 1 |
Huai Heng Loh, Anne Yee, Huai Seng Loh, Norlela Sukor, Nor Azmi Kamaruddin. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Primary Care Diabetes 2016; 10(3): 210 doi: 10.1016/j.pcd.2015.09.001
|
| 2 |
Gillian M. Keating. Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 2014; 74(5): 587 doi: 10.1007/s40265-014-0199-3
|
| 3 |
Syed H. Ahmed, Tahseen A. Chowdhury, Sufyan Hussain, Ateeq Syed, Ali Karamat, Ahmed Helmy, Salman Waqar, Samina Ali, Ammarah Dabhad, Susan T. Seal, Anna Hodgkinson, Shazli Azmi, Nazim Ghouri. Ramadan and Diabetes: A Narrative Review and Practice Update. Diabetes Therapy 2020; 11(11): 2477 doi: 10.1007/s13300-020-00886-y
|
| 4 |
Huai Heng Loh, Nor Azmi Kamaruddin. Treatment Options for Patients with Type 2 Diabetes Mellitus during the Fasting Month of Ramadan. Annals of the Academy of Medicine, Singapore 2020; 49(7): 468 doi: 10.47102/annals-acadmedsg.202060
|
| 5 |
S. Halimi, M. Lévy. Prise en charge des patients diabétiques de type 2 durant le Ramadan : quelle place pour les inhibiteurs de la DPP-4 ?. Médecine des Maladies Métaboliques 2014; 8(3): 299 doi: 10.1016/S1957-2557(14)70804-1
|
| 6 |
Musaab Ahmed, Safaa Badi, Ala Elidrisi, Nazik Elmalaika Husain, Sueziani Binte Zainudin, Arshad Mahmood, Nuha Eljaili Abubaker, Abdullah S. Alghamdi, Mohamed H. Ahmed. Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery. Journal of Diabetes & Metabolic Disorders 2022; 21(2): 1991 doi: 10.1007/s40200-022-01145-6
|
| 7 |
Dana Abdelrahim, MoezAlIslam E. Faris, Mohamed Hassanein, Ayman Z. Shakir, Ayesha M. Yusuf, Aljohara S. Almeneessier, Ahmed S. BaHammam. Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.624423
|
| 8 |
Ehab Mudher Mikhael. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research 2016; 2016: 1 doi: 10.1155/2016/6962574
|
| 9 |
|
| 10 |
Shaun Wen Huey Lee, Jun Yang Lee, Christina San San Tan, Chee Piau Wong. Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics. Medicine 2016; 95(2): e2457 doi: 10.1097/MD.0000000000002457
|
| 11 |
Saud Al Sifri, Kashif Rizvi. Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence. Diabetes Therapy 2016; 7(2): 221 doi: 10.1007/s13300-016-0168-9
|
| 12 |
Mohamed Hassanein, Monira Al-Arouj, Osama Hamdy, Wan Mohamad Wan Bebakar, Abdul Jabbar, Abdulrazzaq Al-Madani, Wasim Hanif, Nader Lessan, Abdul Basit, Khaled Tayeb, MAK Omar, Khalifa Abdallah, Abdulaziz Al Twaim, Mehmet Akif Buyukbese, Adel A. El-Sayed, Abdullah Ben-Nakhi. Diabetes and Ramadan: Practical guidelines. Diabetes Research and Clinical Practice 2017; 126: 303 doi: 10.1016/j.diabres.2017.03.003
|
| 13 |
L. J. Gray, J. Dales, E. M. Brady, K. Khunti, W. Hanif, M. J. Davies. Safety and effectiveness of non‐insulin glucose‐lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 2015; 17(7): 639 doi: 10.1111/dom.12462
|
| 14 |
Fauzia Rashid, Elamin Abdelgadir. A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(2): 1413 doi: 10.1016/j.dsx.2019.02.005
|
| 15 |
Rashmi Shiju, Ayesha Akhil, Smitha Thankachan, Jaakko Tuomilehto, Monira Al Arouj, Abdullah Bennakhi, Ilias Migdalis. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022; 2022: 1 doi: 10.1155/2022/3846253
|
| 16 |
Shaukat Sadikot, K. Jothydev, A.H. Zargar, Jamal Ahmad, S.R. Arvind, Banshi Saboo. Clinical practice points for diabetes management during RAMADAN fast. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2017; 11: S811 doi: 10.1016/j.dsx.2017.06.003
|
| 17 |
Hoda Gad, Tabraiz Hayat, Hamad Al-Muhannadi, Balal Rasheed Malik, Paul Mussleman, Rayaz A. Malik. Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2021; 172: 108562 doi: 10.1016/j.diabres.2020.108562
|
| 18 |
Mohammed Farid Uddin, Murshed Ahamed Khan, Shahjada Selim, Nusrat Sultana, Mohammad Abu Sayem, Mohammed Mahboob Iftekhar, Maruf Bin Habib, Nazma Akter, Shahjamal Khan. Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study. Journal of Comparative Effectiveness Research 2024; 13(2) doi: 10.57264/cer-2023-0132
|
| 19 |
W. J. Wan Seman, N. Kori, S. Rajoo, H. Othman, N. Mohd Noor, N. A Wahab, N. Sukor, N. Mustafa, N. A. Kamaruddin. Switching from sulphonylurea to a sodium‐glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes, Obesity and Metabolism 2016; 18(6): 628 doi: 10.1111/dom.12649
|
| 20 |
Mohamed Khattab, Khalifa Mahmoud, Inass Shaltout. Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study. Diabetes Therapy 2016; 7(3): 551 doi: 10.1007/s13300-016-0190-y
|